View Older Stories View More Recent Stories

May 25, 2016 08:00AM DelMar Pharmaceuticals Announces Successful Completion of End-of-Phase 2 Meeting with FDA on VAL-083 for the Treatment of Refractory Glioblastoma Multiforme
May 19, 2016 10:16AM DelMar Pharmaceuticals Announces Reverse Stock Split in Preparation for Proposed Senior Exchange Uplisting
May 13, 2016 08:00AM DelMar Pharmaceuticals Announces Third Quarter Fiscal Year 2016 Financial Results and Corporate Update
May 5, 2016 08:00AM DelMar Pharmaceuticals, Inc. Announces $5.6 Million Private Placement Of Preferred Shares
Apr 21, 2016 08:00AM FDA Grants Orphan Drug Designation For VAL-083 In Ovarian Cancer
Apr 19, 2016 09:10AM DelMar Pharmaceuticals Updates Ongoing Phase I/II Refractory GBM Clinical Trial with VAL-083 at American Association Cancer Research (AACR) Annual Meeting
Apr 19, 2016 09:00AM DelMar Pharmaceuticals Announces New Data Supporting the Unique Anti-cancer Mechanism of VAL-083
Mar 24, 2016 08:00AM DelMar Pharmaceuticals Announces Abstract Presentations for the American Association Cancer Research (AACR) Annual Meeting in April 2016
Mar 15, 2016 08:30AM FDA Grants Second Orphan Designation For VAL-083
Feb 16, 2016 07:35AM DelMar Pharmaceuticals Announces Second Quarter Fiscal Year 2016 Financial Results and Corporate Update
Feb 4, 2016 07:35AM DelMar Pharmaceuticals to Present at the 18th Annual BIO CEO & Investor Conference on February 8, 2016
Jan 19, 2016 08:00AM MicroCap Review Magazine Winter/Spring 2016 Issue Now Available
Jan 13, 2016 08:05AM DelMar Pharmaceuticals to Collaborate with MD Anderson Cancer Center on Development of DelMar's VAL-083 in Brain Cancer
Jan 6, 2016 08:02AM StockNewsNow.com Publishes New SNNLive Video Interview With DelMar Pharmaceuticals, Inc.
Jan 5, 2016 07:00AM DelMar Pharmaceuticals to Present at the Biotech Showcase™ 2016 on January 12, 2016
Nov 23, 2015 08:05AM DelMar Pharmaceuticals Updates VAL-083 Clinical Trial in Refractory Glioblastoma Multiforme at Society for Neuro-Oncology Annual Meeting
Nov 19, 2015 08:05AM DelMar Pharmaceuticals to Present at the 8th Annual LD Micro Main Event on December 2, 2015
Nov 17, 2015 08:05AM DelMar Pharmaceuticals Reports First Quarter Fiscal Year 2016 Financial Results and Provides Corporate Update
Nov 13, 2015 07:35AM DelMar Pharmaceuticals Presents Data Summarizing the Potential of VAL-083 as a New Treatment Option for Resistant Cancers
Nov 11, 2015 07:35AM DelMar Pharmaceuticals Presents Data Supporting VAL-083 as a Promising Potential Treatment for Pediatric Brain Tumors
Nov 10, 2015 08:05AM DelMar Pharmaceuticals Collaborators Present Data on the Unique Molecular Mechanisms Responsible for VAL-083 Activity Against Cancer
Nov 9, 2015 04:01PM DelMar Pharmaceuticals to Present Updated Phase II Safety and Efficacy Data on VAL-083 in Refractory Glioblastoma Multiforme
Nov 6, 2015 12:15PM DelMar Pharmaceuticals Presents Positive Data on the Benefit of VAL-083 in Combination with Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC)
Nov 5, 2015 09:15AM DelMar Pharmaceuticals to Present at the SeeThruEquity Microcap Investor Forum on November 12, 2015
Oct 21, 2015 08:05AM DelMar Pharmaceuticals Announces the Completion of Enrollment in its Phase II Expansion Study of VAL-083 in Refractory Glioblastoma Multiforme
Oct 19, 2015 07:00AM DelMar Pharmaceuticals Presents Positive Preclinical Data on VAL-083 as a Promising Treatment for Ovarian Cancer
Oct 14, 2015 08:00AM DelMar Pharmaceuticals to Present at the 14th Annual BIO Investor Forum
Oct 13, 2015 08:00AM DelMar Pharmaceuticals Launches Digital Corporate Communication Channels
Sep 29, 2015 07:00AM DelMar Pharmaceuticals to Present Data on the Promising Potential of VAL-083 in the Treatment of Pediatric Brain Tumors
Sep 10, 2015 07:05AM DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme at GBM2015
Sep 4, 2015 07:30AM DelMar Pharmaceuticals Reports Fiscal 2015 Year-End Financial Results and Provides Corporate Update
Aug 27, 2015 08:05AM DelMar Pharmaceuticals to Announce Fiscal 2015 Year-End Financial Results on September 4, 2015
Aug 25, 2015 07:35AM DelMar Pharmaceuticals to Present at the 17th Annual Rodman & Renshaw Global Investment Conference on September 9, 2015
Aug 24, 2015 08:05AM DelMar Pharmaceuticals to Present VAL-083 Lung Cancer Clinical Strategy at the 16th World Conference on Lung Cancer
Aug 20, 2015 07:35AM DelMar Pharmaceuticals Completes $2.6 Million Registered Direct Offering
Aug 17, 2015 08:05AM DelMar Pharmaceuticals Receives Additional Non-Dilutive Funding from NRC-IRAP to Support Expanded Research Program with Lead Product Candidate VAL-083
Jul 27, 2015 09:35AM DelMar Pharmaceuticals Announces Financing Update and Initial Subscriptions of $2.0 million in Registered Direct Offering
Jul 20, 2015 07:35AM DelMar Pharmaceuticals Expands GBM Clinical Trial with Fifth Clinical Trial Site Added in Denver, Colorado
Jul 9, 2015 07:35AM DelMar Pharmaceuticals to Present Updated Phase I/II Clinical Data on VAL-083 in the Treatment of Refractory Glioblastoma Multiforme at GBM2015: 2nd International Symposium on Clinical and Basic Inve
Jun 10, 2015 08:35AM DelMar Pharmaceuticals to Present at the BIO International Convention on June 17, 2015
Jun 1, 2015 02:29PM DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme (GBM) at ASCO
Jun 1, 2015 08:35AM DelMar Pharmaceuticals to Host Investor Conference Call on June 1, 2015 to Discuss New VAL-083 Phase I/II Clinical Data in Patients with Refractory Glioblastoma Multiforme
May 29, 2015 07:35AM DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme
May 27, 2015 07:05AM DelMar Pharmaceuticals Announces Upcoming Investor and Scientific Conference Presentations
May 18, 2015 08:05AM DelMar Pharmaceuticals Announces Third Quarter Fiscal Year 2015 Financial Results and Provides Corporate Update
Apr 30, 2015 07:05AM DelMar Pharmaceuticals to Present Data Supporting the Development of VAL-083 in Refractory Glioblastoma Multiforme and Non-Small Cell Lung Cancer at the American Society of Clinical Oncology (ASCO) An
Apr 20, 2015 01:00PM DelMar Pharmaceuticals Presents Promising Preclinical Data on VAL-083's Potential to Treat Temozolomide-Resistant Glioblastoma Multiforme (GBM)
Apr 20, 2015 08:00AM DelMar Pharmaceuticals Presents Updated Clinical Data on Phase I/II Study of VAL-083 in Refractory Glioblastoma Multiforme (GBM)
Apr 16, 2015 08:05AM DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma
Apr 7, 2015 08:00AM DelMar Pharmaceuticals Announces Panel Participation in Cancer Advance Boston Conference on April 14, 2015
View More Recent Stories View Older Stories